LDN Research Trust

Anxiolytics, adrenergic agents, and naltrexone

J Am Acad Child Adolesc Psychiatry
May 1999
https://pubmed.ncbi.nlm.nih.gov/10230186/

Low Dose Naltrexone (LDN): New in the treatment of chronic pain syndromes. What really matters – reduced pain or increased energy?

A novel glial cell inhibitor, low dose naltrexone, reduces pain and depression, and improves function in chronic pain: A CHOIR study

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants

Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness

Background: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities.

Naltrexone and Scopolamine Rapidly Reduce Symptoms of Major Depressive Disorder (MDD): A Double Blinded Randomized Controlled Pilot Study

Potential antidepressant role of low-dose naltrexone in a rat model of chronic unpredictable mild stress

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

Objective: To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients.

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome

The LDN Shop